Treatment of vulvovaginal erosive and stenosing lichen planus by surgical dilatation and methotrexate

References

• Lewis FM. Vulval LP. Br J Dermatol. 1998; 138: 569–75
   PubMed Web of Science ®Google Scholar
• Micheletti L, Preti M, Bogliatto F, Zanotto-Valentino MC, Ghiringhello B, Massobrio M. Vulval LP in the practice of a vulval clinic. Br J Dermatol. 2000; 143(6)1349–50
   PubMed Web of Science ®Google Scholar
• Kirtschig G, Wakelin SH, Wojnarowska F. Mucosal vulval LP: outcome, clinical and laboratory features. J Eur Acad Dermatol Venereol. 2005; 19(3)301–7
   PubMed Web of Science ®Google Scholar
• Oyama N, Setterfield JF, Gratain MJ, Bhogal BS, Shirlaw P, Challacombe SJ, et al. Oral and genital lichenoid reaction associated with circulating autoantibodies to desmoplakin I and II: A novel target antigen or example of epitope spreading?. J Am Acad Dermatol. 2003; 48: 433–8
   PubMed Web of Science ®Google Scholar
• Pelisse M, Leibowitch M, Sedel D, Hewitt J. Un nouveau syndrome vulvo-vagino-gingival: lichen plan érosif plurimuqueux. Ann Derm Venereol. 1982; 109: 797
   PubMed Web of Science ®Google Scholar
• Edwards L. Vulval LP. Arch Dermatol. 1989; 125: 1677–80
   PubMedGoogle Scholar
• Eisen D. The vulvovaginal-gingival syndrome of LP. Arch Dermatol. 1994; 130(11)1379–82
   PubMedGoogle Scholar
• Rogers RS 3rd, Eisen D. Erosive oral LP with genital lesion: the vulvovaginal-gingival syndrome and the peno-gingival syndrome. Dermatol Clin. 2003; 21(1)91–8
   PubMed Web of Science ®Google Scholar
• Setterfield JF, Neill S, Shorlaw PJ, Theron J, Vaughan R, Escudier M, et al. The vulvovaginal gingival syndrome: a severe subgroup of lichen planus with characteristic clinical features and a novel association with the class II HLA DQB1*0201 allele. J Am Acad Dermatol. 2006; 55(1)98–113
   PubMed Web of Science ®Google Scholar
• Lotery HE, Galask RP. Erosive LP of the vulva and vagina. Obstet Gynecol 2003; 101(5, Part 2)1121–5
   PubMed Web of Science ®Google Scholar
• Mann MS, Kaufman RH. Erosive LP of the vulva. Clin Obstet Gynecol. 1991; 34: 605–14
   PubMed Web of Science ®Google Scholar
• Anderson M, Kutzner S, Kaufman RH. Treatment of vulvovaginal LP with vaginal hydrocortisone suppositories. Obstet Gynecol. 2002; 100: 359–62
   PubMed Web of Science ®Google Scholar
• Cooper SM, Wojnarowska F. Influence of treatment of erosive lichen planus of the vulva on its prognosis. Arch Dermatol. 2006; 142: 289–94
   PubMedGoogle Scholar
• Kirtschig G, van der Meulen AJ, Ion Lipan JW, Stoof TJ. Successful treatment of erosive vulvovaginal LP with topical tacrolimus. Br J Dermatol. 2002; 147(3)625–7
   PubMed Web of Science ®Google Scholar
• Jensen JT, Bird M, LeClair C. Patient satisfaction after the treatment of vulvovaginal erosive LP with topical clobetasol and tacrolimus: a survey study. Am J Obstet Gynecol. 2004; 190: 1759–65
   PubMed Web of Science ®Google Scholar
• Byrd JA, Davis MDP, Rogers RS III. Recalcitrant symptomatic vulvar LP: response to topical tacrolimus. Arch Dermatol. 2004; 140: 715–20
   PubMed Web of Science ®Google Scholar
• Lonsdale-Eccles AA, Velangi S. Topical pimecrolimus in the treatment of genital LP: a prospective case series. Br J Dermatol. 2005; 153: 390–4
   PubMed Web of Science ®Google Scholar
• Borrego L, Ruiz-Rodriquez R, Ortiz de Frutos J, Vanaclocha Sebastián F, Iglesias Diez L. Vulvar LP treated with topical cyclosporine. Arch Dermatol. 1993; 129(6)794
   PubMedGoogle Scholar
• Ridley CM. Chronic erosive vulval disease. Clin Exp Dermatol. 1990; 15: 245–52
   PubMed Web of Science ®Google Scholar
• Ridley CM, Robinson AJ, Oriel JD. Vulval disease. A practical guide to diagnosis and management. Arnold, 2000:132.
   Google Scholar
• Paul MA, Jorizzo JL, Fleischer AB. Low-dose methotrexate treatment in elderly patients with bullous pemphigoid. J Am Acad Dermatol. 1994; 31(4)620–5
   PubMed Web of Science ®Google Scholar
• Bara C, Maillard H. Methotrexate for bullous pemphidoid: preliminary study. Arch Dermatol. 2003; 139: 1506–7
   PubMed Web of Science ®Google Scholar
• Nylander Lundqvist E, Wahlin YB, Hofer PÅ. Methotrexate supplemented with steroid ointments for the treatment of severe erosive lichen planus. Acta Derm Venereol 2002; 82(1)63–4
   PubMed Web of Science ®Google Scholar
• Kazlow Stern D, Tripp JM, Ho VC, Leibwohl M. The use of systemic immune moderators in dermatology: an update. Dermatol Clin. 2005; 23(2)259–300
   PubMed Web of Science ®Google Scholar
• Dubertret L. Methotrexate in dermatology and rheumatology. (Editorial). Joint Bone Spine 2005; 72(2)104–5
   PubMed Web of Science ®Google Scholar
• Franck JM, Young AW, Jr. Squamous cell carcinoma in situ arising with LP of the vulva. Dermatol Surg. 1995; 21(10)890–4
   PubMed Web of Science ®Google Scholar
• Zaki I, Dalziel KL, Solomonsz FA, Stevens A. The under-reporting of skin disease in association with squamous cell carcinoma of the vulva. Clin Exp Dermatol 1996; 21(5)334–7
   PubMed Web of Science ®Google Scholar
• Derrick EK, Ridley CM, Kobza-Black A, McKee PH, Neill SM. A clinical study of 23 cases of female anogenital carcinoma. Br J Dermatol 2000; 143(6)1217–23
   PubMed Web of Science ®Google Scholar
• Becker J, Houben R, Vetter C, Bröcker E. The carcinogenic potential of tacrolimus ointment beoynd immune suppression: a hypothesis creating case report. BMC Cancer 2006; 6: 7 doi 10.1186/1471-2407-6-7.
   Google Scholar